JP2025508542A - Ｐｐａｒｇインバースアゴニストおよびそれらの使用 - Google Patents
Ｐｐａｒｇインバースアゴニストおよびそれらの使用 Download PDFInfo
- Publication number
- JP2025508542A JP2025508542A JP2024552725A JP2024552725A JP2025508542A JP 2025508542 A JP2025508542 A JP 2025508542A JP 2024552725 A JP2024552725 A JP 2024552725A JP 2024552725 A JP2024552725 A JP 2024552725A JP 2025508542 A JP2025508542 A JP 2025508542A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- halo
- compound
- acceptable salt
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317740P | 2022-03-08 | 2022-03-08 | |
| US63/317,740 | 2022-03-08 | ||
| PCT/US2023/063643 WO2023172845A1 (en) | 2022-03-08 | 2023-03-03 | Pparg inverse agonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508542A true JP2025508542A (ja) | 2025-03-26 |
| JP2025508542A5 JP2025508542A5 (enExample) | 2026-03-06 |
Family
ID=86006834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552725A Pending JP2025508542A (ja) | 2022-03-08 | 2023-03-03 | Ｐｐａｒｇインバースアゴニストおよびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250186425A1 (enExample) |
| EP (1) | EP4490147A1 (enExample) |
| JP (1) | JP2025508542A (enExample) |
| CN (1) | CN118984823A (enExample) |
| AU (1) | AU2023231613A1 (enExample) |
| CA (1) | CA3254011A1 (enExample) |
| WO (1) | WO2023172845A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3254026A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Inverse PPARG agonists and their uses |
| CN122122131A (zh) * | 2023-11-10 | 2026-05-29 | 北京丹擎医药科技有限公司 | 杂环衍生物及其组合物和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| US20060217425A1 (en) * | 2005-03-14 | 2006-09-28 | Jack Burton | Methods of treating cancer using PPAR-gamma antagonists |
| CZ300589B6 (cs) * | 2006-09-04 | 2009-06-24 | Univerzita Palackého | Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití |
| CN105982884B (zh) * | 2015-02-25 | 2019-05-24 | 上海中医药大学 | 一种补骨脂二氢黄酮甲醚及其类似物的用途 |
| CN107661333B (zh) * | 2016-07-27 | 2020-12-29 | 清华大学 | 化合物在治疗肺癌中的应用 |
| CN107522657B (zh) * | 2017-09-28 | 2020-06-26 | 上海中医药大学 | 一种具有ppar多重激动活性的化合物及其制备方法和应用 |
| EP3498694A1 (en) * | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
| JP7853310B2 (ja) * | 2021-03-02 | 2026-04-28 | フレア・セラピューティクス・インコーポレーテッド | Ｐｐａｒｇ逆アゴニストおよびその使用 |
| JP2024529534A (ja) * | 2021-08-05 | 2024-08-06 | フレア・セラビューティクス・インコーポレーテッド | Ｐｐａｒｇ逆アゴニストおよびその使用 |
-
2023
- 2023-03-03 AU AU2023231613A patent/AU2023231613A1/en active Pending
- 2023-03-03 CN CN202380033175.XA patent/CN118984823A/zh active Pending
- 2023-03-03 JP JP2024552725A patent/JP2025508542A/ja active Pending
- 2023-03-03 WO PCT/US2023/063643 patent/WO2023172845A1/en not_active Ceased
- 2023-03-03 CA CA3254011A patent/CA3254011A1/en active Pending
- 2023-03-03 EP EP23716983.4A patent/EP4490147A1/en active Pending
- 2023-03-03 US US18/844,419 patent/US20250186425A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4490147A1 (en) | 2025-01-15 |
| WO2023172845A1 (en) | 2023-09-14 |
| US20250186425A1 (en) | 2025-06-12 |
| CN118984823A (zh) | 2024-11-19 |
| AU2023231613A1 (en) | 2024-09-05 |
| CA3254011A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11820747B2 (en) | PPARG inverse agonists and uses thereof | |
| JP7853310B2 (ja) | Ｐｐａｒｇ逆アゴニストおよびその使用 | |
| JP7593647B2 (ja) | ヒストン脱アセチル化酵素阻害剤としての１，３，４－オキサジアゾール誘導体 | |
| EP4380928B1 (en) | Pparg inverse agonists and uses thereof | |
| AU2010219705A1 (en) | Pyridine derivative | |
| TWI429642B (zh) | 用於治療與醯基coA-二醯基甘油醯基轉移酶1活性有關聯之病症之化合物，包含其之醫藥組合物及其用途 | |
| US20250186425A1 (en) | Pparg inverse agonists and uses thereof | |
| JP2025508543A (ja) | Ｐｐａｒｇインバースアゴニストおよびそれらの使用 | |
| HK40118248B (en) | Pparg inverse agonists and uses thereof | |
| HK40118248A (en) | Pparg inverse agonists and uses thereof | |
| EA051641B1 (ru) | Обратные агонисты pparg и их применения | |
| WO2024138211A1 (en) | Pparg inverse agonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260226 |